(Q48035643)

7 February 2018

title

Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome (English)

1 reference

7 February 2018

1 reference

Raspollini MR

1

1 reference

7 February 2018

Amunni G

2

1 reference

7 February 2018

Villanucci A

3

1 reference

7 February 2018

Boddi V

4

1 reference

7 February 2018

Baroni G

5

1 reference

7 February 2018

Taddei A

6

1 reference

7 February 2018

Taddei GL

7

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 March 2004

1 reference

7 February 2018

published in

Gynecologic Oncology

1 reference

7 February 2018

volume

92

1 reference

7 February 2018

issue

3

1 reference

7 February 2018

page(s)

806-812

1 reference

7 February 2018

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Roles of nitric oxide in tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Second-line treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Role of chemotherapy in the management of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Over-the-counter analgesics and risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.023

10.1016/J.YGYNO.2003.12.023

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018